Withania somnifera — sold as ashwagandha, Indian ginseng, or winter cherry — is a small evergreen shrub native to India, North Africa, and the Mediterranean. Its root and, in some preparations, its leaves have been used in Ayurvedic medicine for over 5,000 years as a rasayana: a rejuvenating tonic intended to promote physical vigor, mental clarity, and longevity.
In modern supplement science, ashwagandha is classified as an adaptogen — a plant compound that helps the body buffer the physiological response to stress without acting as a sedative or stimulant. Unlike pharmaceutical anxiolytics, it does not blunt acute cognition. Instead, it modulates the hypothalamic-pituitary-adrenal (HPA) axis over weeks of consistent use, leading to measurably lower cortisol, improved sleep architecture, and, in some populations, meaningful gains in muscle strength and endurance.
What separates ashwagandha from most adaptogens is the quality and depth of the human clinical trial data. While herbs like schisandra or eleuthero have centuries of traditional use but limited RCT evidence, ashwagandha now has dozens of placebo-controlled trials specifically examining cortisol, anxiety scales, sleep quality, and athletic performance. That evidence base is what this guide reviews.
Ashwagandha's bioactivity comes from a family of steroidal lactones called withanolides, along with supporting alkaloids and saponins. Understanding these compounds helps explain why extract quality matters enormously — and why raw ashwagandha powder is rarely the right tool.
The two primary bioactive withanolides are withaferin A and withanolide D. Withaferin A has been shown in cell and animal models to inhibit the NF-κB inflammatory pathway, downregulate heat shock proteins implicated in stress response, and modulate cortisol synthesis at the adrenal level. Withanolide D appears to act partly through androgen receptor pathways, which may explain the testosterone-related findings seen in some trials. Standardized extracts guarantee a minimum percentage of total withanolides (typically 2.5–10%) to ensure consistent potency across batches.
Ashwagandha contains several steroidal alkaloids including withanine and somniferine. These compounds contribute to the herb's mild GABAergic effects — the mechanism most likely responsible for its anxiolytic and sleep-promoting properties. Somniferine in particular is thought to interact with GABA-A receptors, producing calming effects without the dependency risk of pharmaceutical GABA modulators.
Withanosides are glycosides that appear to support neurogenesis and neuroprotection, particularly relevant for cognitive function under chronic stress. Some research suggests withanosides promote BDNF (brain-derived neurotrophic factor) expression, which may partly explain ashwagandha's long-reported mood-stabilizing properties in traditional use.
This is the most cited and methodologically rigorous ashwagandha trial to date. 64 adults with chronic stress were randomized to 300mg KSM-66 twice daily (600mg total) or placebo for 60 days. The ashwagandha group showed a 27.9% reduction in serum cortisol versus 7.9% in placebo. Additionally, DHEA-S — the anabolic counterpart to cortisol — increased by 32%, indicating improved HPA axis balance rather than simple adrenal suppression. Scores on the Perceived Stress Scale (PSS) dropped by 44% in the ashwagandha group versus 5.5% in placebo. All changes were statistically significant (p < 0.0001).
150 healthy adults with mild to moderate sleep complaints received 600mg ashwagandha root extract (KSM-66) or placebo daily for 8 weeks. The treatment group showed significant improvements on the Pittsburgh Sleep Quality Index (PSQI), with reduced sleep onset latency, improved sleep efficiency, and higher scores on mental alertness upon waking. The authors attributed the effect primarily to ashwagandha's triethylene glycol content and its GABAergic alkaloid fraction. Notably, benefits were more pronounced in subjects who reported higher baseline stress.
57 male subjects engaged in resistance training received 300mg KSM-66 twice daily or placebo for 8 weeks. The ashwagandha group showed significantly greater improvements in bench press strength (+46kg vs +26kg), leg extension strength, muscle recovery (via serum creatine kinase), and testosterone levels (+17% vs +4% placebo). Muscle damage markers following exercise were also significantly lower. This remains the benchmark trial for ashwagandha in an athletic context, though sample size is modest.
This systematic review directly compared available ashwagandha extract formulations across multiple trials, examining differences in standardization, dose efficiency, and safety. The review found that KSM-66 (root-only extract) demonstrated the most consistent results across cortisol, anxiety, and cognition endpoints, while Sensoril (root + leaf blend) showed comparable anxiety reductions at lower absolute doses due to higher withanolide concentration. The authors noted that raw ashwagandha powder — unstandardized — produced inconsistent results and should not be used when specific therapeutic outcomes are the goal.
Not all ashwagandha is created equal. The extract form you buy determines the withanolide concentration, the ratio of root to leaf, and ultimately whether the dose you take matches what was used in the clinical trials.
| Form | Source | Withanolides | Typical Dose | Best For |
|---|---|---|---|---|
| KSM-66 | Root only | ~5% | 300–600mg/day | Cortisol, stress, performance — most studied |
| Sensoril | Root + leaf | ~10% | 125–250mg/day | Anxiety, sleep — higher dose efficiency |
| Raw powder | Root (unstandardized) | Varies widely | 3,000–6,000mg/day | Not recommended for clinical outcomes |
KSM-66 is produced via a patented water-based extraction process that preserves the root's full-spectrum withanolide profile without using alcohol or chemical solvents. It has been used in the majority of high-quality human RCTs, making it the default recommendation when cortisol reduction or athletic performance is the goal.
Sensoril incorporates both root and leaf material, achieving a higher withanolide concentration (up to 10%). This means effective doses are smaller in absolute terms. Some users find Sensoril more sedating — useful for evening use or sleep protocols — due to the leaf's higher alkaloid content. For anxiety and sleep specifically, Sensoril is a legitimate alternative to KSM-66.
Raw ashwagandha powder has been used traditionally for millennia, but without standardization, withanolide content can vary 5- to 20-fold between batches. It is not appropriate if you are trying to replicate clinical trial dosing. If you use raw powder for traditional or culinary purposes, that is reasonable — but do not expect predictable therapeutic effects.
Ashwagandha is not a one-size-fits-all supplement. The clinical data points to three populations where the evidence is strongest:
If you have chronically elevated cortisol — whether from work pressure, poor sleep, or systemic inflammation — this is where ashwagandha's evidence is most compelling. The Chandrasekhar 2012 data shows that subjects with higher baseline PSS scores responded more dramatically to supplementation. Ashwagandha works by normalizing dysregulated HPA axis output, so its effects are more pronounced the more dysregulated your baseline is.
The Wankhede 2015 data suggests meaningful strength and recovery benefits for resistance-trained individuals. The mechanism here is dual: lower cortisol means a more favorable anabolic-to-catabolic ratio, and the direct androgen receptor activity of withanolide D may contribute to the observed testosterone increases. Ashwagandha is not a replacement for proper programming or nutrition, but it appears to be a legitimate recovery support tool.
If your sleep disruption is driven by elevated cortisol or anxiety — rather than, say, sleep apnea or circadian misalignment — ashwagandha addresses the root mechanism rather than just inducing sedation. The Langade 2019 data is encouraging, and many users report that it is most effective when sleep problems are stress-adjacent.
Ashwagandha is genuinely stackable — it does not competitively interact with most other common supplements and its mechanisms complement several key stacks.
L-theanine (200–400mg/day) promotes alpha-wave brain activity and reduces acute stress reactivity via glutamate receptor modulation. Ashwagandha addresses chronic HPA axis dysregulation over weeks. Together they provide both immediate and sustained stress buffering — L-theanine handles the acute spike while ashwagandha resets the baseline. This is one of the most commonly recommended adaptogen stacks and has no known negative interactions.
Magnesium glycinate (300–400mg elemental magnesium, taken 30–60 minutes before bed) acts on NMDA receptors and GABA pathways to reduce sleep onset latency and improve slow-wave sleep depth. Pairing it with ashwagandha (taken in the evening) creates complementary GABAergic support. This combination is particularly useful for stress-driven insomnia where the mind remains active at bedtime.
Rhodiola rosea (200–400mg standardized to 3% rosavins) is an adaptogen with an energizing profile — it reduces mental fatigue and improves cognitive performance under stress, largely via monoamine and opioid receptor modulation. Where ashwagandha is calming and restorative, rhodiola is activating and performance-focused. The combination covers both ends of the stress response spectrum. Use rhodiola in the morning and ashwagandha in the evening for best results.
In the major RCTs reviewed above, ashwagandha at 300–600mg/day KSM-66 was well-tolerated with adverse event rates comparable to placebo. The risk profile at evidence-based doses is low for healthy adults with no contraindicated conditions.
Ashwagandha is one of the most evidence-supported adaptogens available. Unlike many supplement categories where the human trial data is sparse or industry-funded, ashwagandha has accumulated a meaningful body of independent RCT evidence across cortisol reduction, anxiety, sleep quality, and athletic performance.
The practical protocol is straightforward: 600mg KSM-66 per day, taken with food, for a minimum of 8 weeks before assessing response. Those targeting sleep specifically may prefer 125–250mg Sensoril in the evening. Cycle off for 2 weeks every 3 months as a precaution.
The key caveats: it is not a quick-fix anxiolytic. It will not provide the immediate relief of L-theanine or magnesium taken acutely. Its benefits accumulate over weeks as it recalibrates HPA axis output. For people with genuinely elevated chronic stress, poor sleep driven by anxiety, or athletes looking to optimize recovery and anabolic balance, it has a legitimate place in the stack.
For most users, a high-quality KSM-66 extract at 600mg/day is the starting point. Look for third-party tested products that clearly state the extract form and withanolide percentage on the label. Avoid products that only list "ashwagandha root powder" without standardization.
→ View KSM-66 Ashwagandha on AmazonStackProtocol participates in the Amazon Associates program. If you purchase through our links, we may earn a small commission at no extra cost to you. This does not influence our recommendations — we only recommend products that align with the clinical evidence reviewed above.
As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.